About: Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis
Creator	Luo, Shanshan Aloysius, Mark Bansal, Pardeep Gajendran, Mahesh Goyal, Hemant Marotta, Francesco Perisetti, Abhilash Trebicka, Jonel Boregowda, Umesha
source	Medline; PMC
abstract	Background: Abnormal liver chemistries are common findings in patients with COVID-19. It is unclear whether abnormal liver chemistries can predict the severity of COVID-19. Therefore, we compared the serum liver chemistries such as hepatic transaminases, total bilirubin, albumin, and prothrombin time to evaluate whether they can predict severity and mortality in COVID-19. Methods: An electronic search was performed on PubMed/Medline, EMBASE, and Google Scholar for studies comparing liver chemistries in severe and mild COVID-19. The literature search was performed using keywords “COVID-19,” “Liver,” Aspartate Aminotransferase (AST),” and “Alanine Aminotransferase (ALT),” “AST,” and “ALT,” in various combinations of “AND/OR” from December 1, 2019, till May 8, 2020. The pooled weighted mean difference (WMD) and 95% confidence interval (CI) were calculated for each component of liver chemistries. Results: Twenty-two studies were eligible, with 3,256 patients (54.57% males). Seventeen studies compared liver chemistries for severe vs. mild COVID-19, whereas five studies compared liver chemistries in survival vs. non-survival groups. The pooled WMD of AST and ALT in severe vs. mild COVID-19 were 12.23 (95% CI; 8.07, 16.39; p < 0.01) and 8.07 (95% CI 2.55, 11.91; p < 0.01), respectively. The pooled WMD for AST in survivors vs. non-survivors analysis was 8.82 (n = 789; 95% CI; 2.27, 15.37; p < 0.01) and that of ALT was 4.70 (n = 340; 95% CI 0.04,9.35; p = 0.05). Conclusion: Our meta-analysis shows that deranged liver chemistries may indicate severe COVID-19 and could also predict mortality. Larger studies are needed to evaluate the relationship between derangement in liver chemistries and mortality in COVID-19.
has issue date	2020-07-22(xsd:dateTime)
bibo:doi	10.3389/fmed.2020.00431
bibo:pmid	32793616
has license	cc-by
sha1sum (hex)	8f677723f22ff19dab033978df0695a4627a812c
schema:url	https://doi.org/10.3389/fmed.2020.00431
resource representing a document's title	Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis
has PubMed Central identifier	PMC7387424
has PubMed identifier	32793616
schema:publication	Front Med (Lausanne)
resource representing a document's body	covid:8f677723f22ff19dab033978df0695a4627a812c#body_text
is schema:about of	named entity 'liver' named entity 'liver' named entity 'transaminases' named entity 'COVID-19' named entity 'Liver Enzymes' named entity '0.01' named entity 'lymphocytes' named entity 'AST and ALT' named entity 'secondary bacterial infections' named entity 'hepatocytes' named entity 'chronic liver disease' named entity 'WMD' named entity 'COVID-19' named entity 'low serum albumin' named entity 'COVID' named entity 'muscle injury' named entity 'etiology' named entity '1, 2' named entity 'low albumin' named entity 'forest plot' named entity 'COVID' named entity 'COVID' named entity 'steatosis' named entity '95% CI' named entity 'province in China' named entity 'abdominal pain' named entity 'COVID' named entity 'liver' named entity 'autopsy' named entity 'Figure 8' named entity 'Liver' named entity 'elevated liver enzymes' named entity 'elevated liver enzymes' named entity 'transaminitis' named entity 'COVID' named entity 'respiratory rate' named entity 'shortness of breath' named entity 'liver dysfunction' named entity 'liver injury' named entity 'ACE-2' named entity 'coronavirus' named entity 'receptor' named entity 'Heterogeneity' named entity 'prothrombin time' named entity '0.01' named entity 'Hozo' named entity 'ICU' named entity 'chronic liver disease' named entity 'liver injury' named entity 'SARS-CoV-2 virus' named entity 'hepatic' named entity 'lymphocyte count' named entity 'albumin' named entity 'Secondary bacterial infections' named entity '0.01' named entity '95% CI' named entity 'virus-mediated' named entity 'observational studies' named entity 'Center for Disease Control and Prevention' named entity 'liver' named entity 'lactate dehydrogenase' named entity 'prognosis' named entity 'anti-tubercular medications' named entity 'virus' named entity 'liver' named entity 'United States' named entity 'liver injury' named entity 'spike protein' named entity 'Google Scholar' named entity 'receptor' named entity 'COVID' named entity 'Cochrane' named entity 'prognostication'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software